Brutalist Biotech

• Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication (18h)
• BrightGene tops Novo drug in diabetes ahead of Zepbound showdown (19h)
• Corxel, Sciwind post GLP-1 data as China's obesity push gathers pace (19h)
• Leap expands layoffs to cover 75% of employees, scraps only clinical trial to save cash (20h)
• Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed (20h)
• Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock soaring (21h)
• Otsuka pens $670M pact to point Harbour’s preclinical T-cell engager to autoimmune disease (22h)
• Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential (1d)
• Vertex’s remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test (1d)
• Abbott lines up insulin pump collabs for its upcoming glucose-ketone sensor (3d)
• Miniature robot maker Virtual Incision nabs new CEO (3d)
• The World Can’t Wait: Delivering on the Promise of Biopharma’s “Golden Age” Mina Makar, Senior Vice President, Global Cardiovascular, Renal and Metabolism, AstraZeneca (3d)
• FDA blocks new clinical trials that ship cells from US to China (3d)
• Syncona blames 'challenging' market for shift in biotech investment strategy (4d)
• Prothena lays off 63% of employees in fallout from phase 3 amyloidosis drug fail (4d)
• Industry ‘deeply disappointed’ as FDA puts cell and gene therapy chief on administrative leave (4d)
• Chutes & Ladders— BMS banks on Wall Street vet for long-term strategy guidance (5d)
• Arialys' precision therapy shows promise in rare encephalitis disorder and beyond (5d)
• Zealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeks (5d)
• Grail plans to submit updated Galleri blood test for FDA approval next year (5d)

• Relentless innovation: Bold exploration in advancing therapeutic options for every patient, every discovery (13h)
• Top drug official at FDA reportedly set to exit next month (13h)
• Cidara stock soars as antiviral drug succeeds in flu study (16h)
• Novo abruptly ends obesity drug deal with Hims (16h)
• Compass’ big psychedelic study doesn’t impress investors (17h)
• Illumina to buy SomaLogic in deal worth up to $425M (17h)
• [Podcast] Trial Trailblazers: Behind clinical breakthroughs (20h)
• The rise of GLP-1 drugs: Transforming weight loss treatment (23h)
• Prothena to lay off majority of staff; Zealand shares obesity drug data (3d)
• A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups (3d)
• Gene therapy faces fresh uncertainty as two more top FDA officials depart (3d)
• FDA approves twice-yearly shot of Gilead drug for HIV prevention (5d)
• Scholar Rock drug preserves muscle in obesity trial (5d)
• Draig, a brain drug startup, debuts with $140M to treat depression (5d)
• FDA to speed reviews for drugs supporting ‘national interests’ (5d)
• A startup banks $65M to pursue ‘inclusive precision medicine’ (5d)
• Lilly to acquire Verve in $1B bet on gene editing for heart disease (6d)
• FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction (6d)
• Could the FDA take an indirect approach to regulate lab developed tests? (1w)
• Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug (1w)

• Politics collide with science ahead of new ACIP meeting (12h)
• Amgen plans more gradual MariTide dosing in Phase 3 (12h)
• FDA approves AstraZeneca, Daiichi Sankyo's Datroway in EGFR-mutated lung cancer (12h)
• Roche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3 (12h)
• Supreme Court asks DOJ to weigh in on Hikma ‘skinny label’ fight (16h)
• Exelixis' positive Phase 3 colorectal cancer data boost stock (17h)
• Novo Nordisk ends partnership with Hims over compounded drugs (17h)
• Formation Bio’s up to €545M licensing deal with Sanofi; Otsuka, Harbour BioMed team up (17h)
• Cidara's preventive influenza biologic is effective in Phase 2b trial (17h)
• Acting CDER chief to depart FDA in July (18h)
• #ADA25: Lilly’s bimagrumab boosts weight and fat loss when added to Novo's Wegovy (19h)
• Illumina to buy SomaLogic for $350M, pushing further into proteomics (21h)
• Compass reports Phase 3 depression data for psilocybin drug (22h)
• A puzzling update from Novo Nordisk and new data from Roche at #ADA25 (2d)
• FDA unveils new pilot program; Sage finds a buyer; Eli Lilly to acquire Verve; and more (3d)
• #ADA25: Vertex's diabetes cell therapy allows 10 patients to come off insulin (3d)
• CHMP recommends five new drugs, reconsiders Eli Lilly’s Kisunla (3d)
• FDA to biotech CEOs: US is lagging behind on early-stage trials (3d)
• Pharma companies are weighing up how a drug’s IP location could impact tariffs (3d)
• UK's NICE says Alzheimer’s drugs aren't worth national coverage (3d)

• Washington's Policy Shifts Are Driving Capital Away From Life-Saving Research (4h)
• FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent (4h)
• Acting CDER Head Becomes Latest in String of FDA Leaders to Leave Agency (16h)
• Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack (17h)
• Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’ (18h)
• Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III (19h)
• Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression (19h)
• Prothena Downsizes by 63% in Aftermath of AL Amyloidosis Failure (20h)
• Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain (20h)
• IRA Leaves Orphan Drugs Stranded Even as Regulators Promise Progress (1d)
• Experts Say Axed ACIP’s Conflicts of Interest Are ‘a Red Herring’ (1d)
• 8 Companies Hiring in San Diego (3d)
• Zealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for More (3d)
• Cycle Wins First FDA Nod for Ultra-Rare Genetic Disease (3d)
• FDA Freezes Trials Shipping Cells to China, ‘Other Hostile Countries’ (3d)
• Life Sciences Employment Growth in California Slows—and Could Keep Slowing (4d)
• Navigating Funding Freezes and AI Frontiers (4d)
• Quick on Its Feet: Novavax Adapts to Continued Regulatory Uncertainty (4d)
• Nicole Verdun Exits FDA as CBER Director Vinay Prasad ‘Consolidates Power’ (4d)
• Gilead Wins Historic Approval for Twice-Yearly HIV Drug (5d)

Bio IT World

• Pangaea Data, Alexion Collaboration, Dell to Develop Supercomputer, More (3h)
• Nanoneedle Patch Enables Non-Invasive Tissue Sampling Offering Spatiotemporal Insights (5d)
• Black Swan Initiative: Multi-Pronged Research Strategy Targets Multiple Myeloma Cure (6d)
• Pistoia Alliance’s FAIR Maturity Assessment Tool (1w)
• Veteran ‘Lord of the Flies’ Takes a Crack at Addiction (2w)
• NVIDIA, Novo Nordisk Collaborate to Bring AI Agents to Drug Discovery (2w)
• A Farewell to Stan Gloss: Leading with Generosity and Other Words of Wisdom (2w)
• MIT Researchers Unveil Boltz-2: AI Model Predicts Protein Structure, Binding Affinity in Seconds (2w)
• Smart Bandage Merges Sensor Technology, Microfluidics, and AI (3w)
• A Practical Precision Medicine Approach to Complex Chronic Diseases (3w)
• Follow the Money: Pathos AI Drug Development Platform, Stylus Medicine’s In Vivo Advancements, More (4w)
• Illumina’s Newest DRAGEN, Lupus Research Alliance Launches Dataset, More (4w)
• The ALL ALS Consortium’s Open Science Initiative (4w)
• CURATE.AI: How Digital Twins Are Revolutionizing Precision Dosing (1mo)
• Innovative Practices Winner: Chromatography Data Management (1mo)
• Regeneron Acquires 23andMe for $256 Million (1mo)
• Trends from the Trenches: Data, Discovery, Politics (1mo)
• Sweden's PROMISE Initiative: Bridging Research and Healthcare Through Multi-Omics (1mo)
• CFDE Unites Data Enthusiasts During Hackathon before Kick-Off of Bio-IT World Conference (1mo)
• MiLabs Launches Platforma: Bridging the Gap Between Biology and Bioinformatics (1mo)

• Cassidy calls to delay meeting of CDC’s vaccine panel in challenge to RFK Jr. (8h)
• Health insurers promise to reduce barriers to care under pressure from Trump administration (11h)
• GLP-1 drug helped type 1 diabetes patients keep healthy glucose levels and lose weight (12h)
• Vertex stem cell therapy spurs insulin independence (13h)
• The Senate’s version of Trump’s tax-cut bill threatens safety-net hospitals like ours (13h)
• Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing (14h)
• The number of abortions kept rising in 2024 because of telehealth prescriptions, report finds (14h)
• Senate Republicans discuss new way to cut Medicaid in Trump’s tax bill (16h)
• Top drug regulator is retiring as FDA departures mount (18h)
• Compass psilocybin therapy shown to be effective in largest-ever study in depression (18h)
• MAHA eyes tolerance as alcohol-related harms emerge (19h)
• We’re reading about Novo ending Hims deal, FDA transparency, and more (19h)
• Eli Lilly drug preserves lean mass in patients losing weight on Wegovy (19h)
• Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs (19h)
• FDA chief’s goals of ‘radical transparency’ threatened by agency cuts (1d)
• The decades-long journey to Gilead’s twice-a-year HIV prevention drug lenacapavir (1d)
• Health care costs: one of the biggest obstacles to reshoring American industry (1d)
• Novo Nordisk’s amylin obesity drug keeps performing like Zepbound (1d)
• Full data on Novo Nordisk’s new amylin drug raise dosing questions (3d)
• Off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results (3d)

• NVIDIA Releases Agentic AI Blueprint for Literature Review and Target Discovery (4d)
• Nabla Raises $70M Series C to Expand Agentic AI Platform for Clinical Workflows (5d)
• Axiom Bio Releases Human Liver Toxicity Dataset with 130,000 Compounds to Advance AI-based Toxicity Prediction (5d)
• Xaira Publishes Largest Public Perturb-seq Atlas to Advance Virtual Cell Modeling (6d)
• Agenus and Noetik Partner to Develop AI-Based Biomarkers Using Virtual Cell Models (6d)
• Isomorphic Labs Appoints Ben Wolf as Chief Medical Officer, Expands to U.S. Hub in Cambridge (6d)
• Ryght AI Raises $3M to Automate Clinical Trial Site Activation with Agentic AI (1w)
• AstraZeneca Signs $5.3B AI Drug Discovery Deal with CSPC for Chronic Disease Programs (1w)
• Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million (1w)
• Sofinnova Partners and NVIDIA Collaborate to Provide GPU Access to AI-Driven Life Sciences Startups (2w)
• Insilico Medicine Launches its Multimodal Generative Chemistry Model on AWS Marketplace (2w)
• FutureHouse Debuts Scientific Reasoning LLM Model Trained for Chemistry (2w)
• MIT and Recursion Launch Boltz-2, Open-Source AI Foundation Model for Structure and Binding Affinity Prediction (2w)
• The Stage Is Set: London Biotechnology Show 2025 (2w)
• FDA Launches Internal AI Tool "Elsa" to Streamline Regulatory and Scientific Workflows (2w)
• Sarepta Secures First FDA Platform Designation for Gene Therapy Delivery Technology (2w)
• Kiin Bio Raises $2.2M Pre-Seed to Build AI Platform of "Virtual Scientists" for Drug Discovery (2w)
• Using AI, ImmunoPrecise Discovers Possible Universal Dengue Vaccine Target (2w)
• Antheia Raises $56M Series C to Scale Biosynthetic Drug Ingredient Production, Expands to Asia (3w)
• Nature Medicine: AI-Designed TNIK Inhibitor Shows Lung Function Gains in IPF (3w)

• Turning plastic into medicine: Closing the loop on pharma production (17h)
• Special Episode: The 2025 BIO International Convention (4d)
• Stem cell therapy: a potential cure for hearing loss? (4d)
• 10 cultured meat companies driving sustainable food in 2025 (5d)
• From undruggable to oral therapy: The rise of STAT6 degraders (6d)
• Six kidney disease companies you should know about in 2025 (6d)
• Did Novo open the Canadian market to GLP-1 generics? (1w)
• A new era in migraine treatment: Innovative drugs redefining the field (1w)
• Alex Telford on AI, drug discovery, digital twins, and the most interesting questions in biotech (2w)
• Behind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure? (2w)
• Can gene therapy treat vision loss? (2w)
• Pushing biotech forward in France: 18 companies to know about (2w)
• First antibiotic in 50 years to tackle superbug nears approval: what’s going on in the field? (2w)
• Beyond CRISPR: What CAST could bring to genome editing (2w)
• Corporate venture capital and biotechnology in 2025: challenges, opportunities, and threats (3w)
• The biggest biotech funding rounds in May 2025 (3w)
• ASCO 2025: key highlights in cancer therapeutics (3w)
• How biotechs are developing novel treatments to tackle high cholesterol (3w)
• Top biotech deals in May 2025 (3w)
• London: A closer look at the UK capital’s world-renowned biotech hub (3w)

• Brain Receptor Structure Revealed to Support Cerebellum Function Repair (6h)
• Scientific Data Crisis Holds Back CMC (11h)
• Rare Gene Mutation Delays Alzheimer’s by Damping Immune Cell Inflammatory Signaling (12h)
• Potency Assays in Cell and Gene Therapy: Strategies for Manufacturing and Regulatory Success (12h)
• Novel Molecule May Rival GLP-1 Agonists for Diabetes and Obesity Treatment (17h)
• Novel Molecule May Rival GLP-1s for Diabetes and Obesity Treatment (17h)
• Illumina to Acquire SomaLogic from Standard BioTools (17h)
• LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma (20h)
• StockWatch: CGT Stocks Fall on FDA Therapeutic Products Upheaval (1d)
• Intercellular Fluid Flow Impacts Tissue Response to Physical Forces (3d)
• Intercellular Fluid Flow Impacts Tissue Response to Physical Forces (3d)
• US Pharmacopeia Recognizes Mass Photometry in New AAV Reference Standards for Gene Therapy Quality (3d)
• BIO 2025, Huge Virtual Cell Dataset, AI-Designed De Novo Proteins (3d)
• At BIO, Companies Launch New Products for AAV Manufacturing, AI Drug Discovery (3d)
• King Faisal Specialist Hospital & Research Center and Germfree Labs Agree to Develop Advanced Therapy Manufacturing Campus in Riyadh (3d)
• Nanoparticle Drug Delivery System Improves Stability and Drug Loading (4d)
• Bionova Scientific Expands Capacity and Joins Advanced Therapies Market (5d)
• QurAlis Opens New Global Headquarters (5d)
• Personalized mRNA Meds Driving Demand for Small-Scale Production (5d)
• Turning Forestry Waste into Biopharmaceuticals (5d)

• Faith, Friendship and Finding Purpose After Breast Cancer (11h)
• A New Digital Platform Aims to Expand Access to Early Oncology Trials (13h)
• FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer (14h)
• Living My Best Life: A Family Beach Vacation After a Brain Tumor (15h)
• Spotlighting Pancreatic Cancer Disparities in Black Communities (16h)
• Illuccix is FDA Approved to Guide Radioligand Use in Prostate Cancer (17h)
• What Should Patients with Multiple Myeloma Know After ASCO 2025? (19h)
• Improving Distant Control in Lung Cancer With JNJ-1900 and Keytruda (1d)
• Experts Impart Notable Information and Updates for Those With Blood Cancers (1d)
• Breaking Down Clinical Trial Participation in Kidney Cancer: Is it Right for You? (2d)
• What Patients With Polycythemia Vera Should Know After ASCO 2025 (2d)
• Radiation and Resilience: Laughing Through the Hardest Days (3d)
• Clinical Trial Corner: New Treatments in Leukemia, Lymphoma and Brain Cancers (3d)
• The Path Forward: Thriving in Cancer Survivorship (3d)
• Advancements Reshape Treatment for Non-Small Cell Lung Cancer (3d)
• Personalized Therapy Helps Tailor Treatment for GIST (3d)
• Can ctDNA Help Guide Surgical Decision Making in Breast Cancer (3d)
• Self-Advocacy Can Help Patients Navigate Cancer Treatment Challenges (4d)
• Experts Walk Through Recent Hematologic Malignancy Treatment Updates (4d)
• Breaking Down the Impact of SERENA-6 for Some With Breast Cancer (4d)

Contract Pharma*

• Novo Nordisk Axes Relationship with Hims & Hers (13h)
• Celltrion Opens UK Headquarters in Uxbridge (18h)
• Why Project Management Is the Real Differentiator for CDMOs (18h)
• Cellular Origins, Johnson & Johnson Partner for CGT Robotics Manufacturing Platform (18h)
• Nutriband, Kindeva Complete Commercial Scale-up for Aversa Fentanyl (18h)
• Pharmalogic Acquires Majority Stake in Agilera Pharma (18h)
• Formation Bio Licenses Gusacitinib to Sanofi (19h)
• Harbour BioMed, Otsuka Partner to Advance Bispecific T-Cell Engagers (19h)
• Ferring Opens New Gene Therapy Manufacturing Facility (3d)
• Pharmaceutical Contract Manufacturing and Research Services - GlobeNewswire (3d)
• Pharmaceutical Contract Manufacturing and Research Services Market Report 2025-2030 | Demand for Affordable Generics and Biosimilars Drives Growth in Contract Pharma Services - Yahoo Finance (3d)
• Enzene Expands Biomanufacturing Operations at New Jersey Site (3d)
• Sanner Launches Manufacturing Ops in Greensboro, NC (3d)
• Kindeva, Rocket Science Health Create New Intranasal Delivery Platform (4d)
• Delpharm Invests in Saint-Rémy Site to Support Aseptic Vials (4d)
• LOTTE Biologics, Ottimo Pharma Sign Antibody Manufacturing Contract (4d)
• RyboDyn Selected to Join Lilly Gateway Labs (4d)
• Veranova Breaks Ground on ADC Facility Expansion (4d)
• Bend Bioscience Opens Four New Process Development & Mfg. Suites in Oregon (4d)
• Antares Vision Group Launches AI-Driven Visual Inspection Platform (4d)

• NHS rolls out new initiative to identify pancreatic cancer earlier (21h)
• eXmoor and Signadori Bio enter cell therapy partnership (4d)
• Teva and Fosun Pharma partner on early-stage oncology drug (5d)
• FDA approves UroGen’s Zusduri to treat recurrent bladder cancer (6d)
• EDX medical partners with spire healthcare to advance disease diagnostics (1w)
• Investigational treatment shows promise for aggressive multiple myeloma (1w)
• Levicept presents new LEVI-04 data at EULAR (2w)
• Migraine takes the spotlight at European Parliament (2w)
• Bimekizumab shows lasting efficacy at EULAR 2025 (2w)
• Argenx presents new efgartigimod data at EULAR 2025 (2w)
• Tagomics secures £860k grant for colorectal cancer test (2w)
• PharmaTimes Clinical Researcher of the Year – The Americas (2w)
• European Commission approves Santen’s Ryjunea to slow progression of paediatric myopia (3w)
• Linear Diagnostics awarded £1m to develop rapid STI test (3w)
• Patient puzzle (3w)
• NICE recommends Sogroya for growth hormone deficiency in children (3w)
• PharmaTimes Clinical Researcher of the Year – The Americas (3w)
• NICE recommends mirikizumab for Crohn’s disease treatment (3w)
• AstraZeneca’s Forxiga recommended for chronic kidney disease treatment (3w)
• Lumanity and Parker Institute partner to support delivery of new immunotherapies (4w)

• More Than 50 Health Plans Commit to Simplifying Prior Authorization (8h)
• Why This Former OpenAI Exec Is Urging Health Leaders to ‘Specialize in Empathy’ (9h)
• Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence (13h)
• The Overlooked Global Warming Cost We Can’t Ignore (18h)
• The Medicaid Reckoning: Era of Fiscal and Policy Flux (19h)
• New Cohere Health Solution Aims to Streamline Clinical Reviews for Payers (1d)
• Precision Medicine Firm Caris Breaks Bio IPO Drought, Raising $494M for Cancer Analysis Tools (1d)
• Why Intermountain Health Is Investing In AI for Clinical Data Abstraction (1d)
• What OpenAI’s o3 Price Drop Means for the Future of AI in Healthcare? (1d)
• The MFN Executive Order: A Global Reset for U.S. Pharma (1d)
• Bluebird Kids Health to Expand By Opening New Pediatric Clinics (3d)
• Sword Health Raises $40M, Launches Mental Health Solution (3d)
• Draig Therapeutics Emerges With $140M for Clinical Tests of Novel Neuropsychiatric Drugs (3d)
• How Emerging Hospital Bed Technology Can Help Patients Rest Easier And Recover Faster (3d)
• The Top Patient Engagement Tools for Behavioral Health Organizations (3d)
• AI Governance: Building Trust and Transparency for Healthcare AI (3d)
• Taking The Wheel: A Proactive Approach to Improving Longevity (4d)
• The Benefits of Establishing a Data-driven Culture in Healthcare (4d)
• Discover the Hidden Costs of Siloed Systems (4d)
• Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug (5d)

• Veolia opens PFAS removal plant in Delaware (12h)
• Crystals defy their symmetry to discern chiral light (14h)
• Researchers turn plastic into paracetamol (16h)
• How air pollution can cause kidney disease (18h)
• Draig Therapeutics flies out of stealth to treat depression (3d)
• Machine learning helps improve accuracy and efficiency of small-molecule calculations (3d)
• Chairs of 36 US chemistry departments call to restore funding (4d)
• Executives, investors stick to basics at BIO 2025 (4d)
• Podcast: Can altering ocean chemistry fight climate change? (4d)
• Acetic acid breaks down carbon fiber–reinforced polymers (5d)
• Lilly to acquire Verve Therapeutics for $1.3 billion (5d)
• NSF names 504 new graduate research fellows (5d)
• Reactions: ACS’s response to Trump, and US funding decisions (5d)
• Chemistry in Pictures: Porphyrin pellets (5d)
• Call for applications: 2026 ACS PRIDE Merck Graduate Research Award (5d)
• A more effective carbon dioxide reduction reaction (5d)
• Missile strike hits Weizmann Institute of Science lab buildings (6d)
• Scientists identify pathway for key Taxol precursor (6d)
• Business briefing for June 23 (6d)
• Multifunctional chemistry claims space in personal and home care (6d)

The Pharma Letter*

• Lilly’s oral GLP-1 shows no liver safety issues in Phase III diabetes trial (15h)
• Medicus Pharma appoints COO; updates on SKNJCT-003 (15h)
• European approval for argenx expands autoimmune footprint (15h)
• Despite topline trial success, Compass going in wrong direction (15h)
• Otsuka in-licenses Harbour BioMed’s HBM7020 (17h)
• Industry anger at FDA oustings (17h)
• Ono to sell Vertex’s povetacicept in Japan (18h)
• Positive Phase III Study of Winrevair in PAH (18h)
• New data demonstrates robust efficacy of Vyepti in severe migraine (19h)
• EFPIA underlines its role in disclosure of pharma payments (19h)
• Idorsia-expands Quviiq into China as Simcere receives NDA approval (21h)
• Vertex presents positive data for zimislecel in type 1 diabetes (22h)
• Positive new data on Roche’s Lunsumio and Polivy combo (22h)
• Innovative medicines: where does the Netherlands stand? (22h)
• Cycle Pharmaceuticals (22h)
• New data on Novo’s next-gen obesity drugs and hemophilia challenger (22h)
• Achieve adds vapers to smokers in targeting multi-billion dollar market (23h)
• The week in pharma: action, reaction and insight – week to June 20 (1d)
• Draig Therapeutics (2d)
• MHRA approves UK’s first anti-PD-1 MAb for aggressive form of lung cancer (2d)

• Walking Through the First 3 Physician Visits for Patients with mHSPC (13h)
• Zanzalintinib/Atezolizumab Improves CRC Survival, Expands TKI's Role in Solid Tumors (14h)
• FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC (14h)
• Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL (14h)
• Dr Muvner on Targeted Therapies in Prostate Cancer (15h)
• Hochhaus on ASC4START and Asciminib’s Superior Tolerability in CML-CP (16h)
• Dr Abramson on ASCO 2025 DLBCL Updates: What's New? (17h)
• FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML (18h)
• Mismatched Unrelated Donors & PTCy: Better HSCT Outcomes, Expanded Access (18h)
• Navigating the Treatment Landscape in Non–Clear Cell Renal Cell Carcinoma (19h)
• Treatment Evaluation and Modification Considerations in mCRPC (20h)
• Management and Monitoring of Adverse Events in mCRPC (20h)
• Dr Morgans Provides Prostate Cancer Updates From ASCO 2025 (1d)
• ISGIO Conference Highlights Emerging Trial Results Shaping GI Cancer Care (1d)
• The Targeted Pulse: A Weekly Dose of Oncology Updates (1d)
• Talquetamab/Teclistamab Combo Shows High, Durable Responses in RRMM With EMD (2d)
• Defining the Role of Consolidative Thoracic Radiotherapy Post Immunotherapy in ES-SCLC (2d)
• Pembrolizumab and Chemoradiation Deliver Durable Responses in Stage III NSCLC (2d)
• Zanubrutinib Shows PFS Benefit Over Acalabrutinib/Venetoclax in CLL (3d)
• Exploring Genomic Assays for Early-Stage Breast Cancer Treatment (3d)

• Analyst: Novo Nordisk shows “decisiveness” by dropping partner after dispute over generic drugs (3m)
• Him & Hers boss hits back after Novo's decision to end partnership (42m)
• Lundbeck drug granted special status in Europe and the US (1h)
• CHMP recommends 13 new medicines for approval – and makes use of rare exception rule (1h)
• Novo Nordisk ends collaboration with US partner after two months (19h)
• GN gains market share among US veterans in May (19h)
• Trump's "most favored nation” policy puts pressure on EU pharma industry (20h)
• Eli Lilly expects results from obesity candidate in the third quarter (22h)
• Novo Nordisk presents detailed data on weight loss candidate cagrisema (23h)
• Novo Nordisk presents data on higher dose of Wegovy (23h)
• Novo's weight loss drug approved by US cardiologists (1d)
• EU to restrict China’s access to medical device procurements (1d)
• Zealand Pharma stock down 45% this year: Hit by publicity drought (3d)
• Lundbeck wants aggressive life science strategy: EU position "can quickly erode" (3d)
• Eli Lilly to appeal UK reimbursement denial for Alzheimer's drugs (4d)
• Fruergaard reassures employees that replacement will align with company values (4d)
• Ambu receives approval for new disposable endoscope for the US market (4d)
• EU increasingly resigned to 10% mutual tariff with the US (4d)
• Professor on Lars Rebien's power in the Novo Group: "The return of the king" (4d)
• Bavarian Nordic's USD 160m voucher sale indicates rising value (4d)

• Hexanitrogen (11h)
• Stir Bars Can't Be Ignored (5d)
• AI Effects on Drug Patents (1w)
• Mirror Morphine (2w)
• Vaccine Advice, Vandalized (2w)
• Novo Nordisk's Canadian Mistake (2w)
• The Bethesda Declaration (2w)
• Taurine and Aging: Is There Anything to It? (2w)
• Cleaning Up the Medical Literature (3w)
• Not One of Your Easy Crystals (3w)
• The Continuing Crisis, Part XV: The Horrendous Trump Budget (3w)
• Taurine Revisited (3w)
• A New Route to Asthma Treatment - Through the Liver, of All Places (4w)
• One Drug's Supply Chain, In Detail (4w)
• A Reaction to Alzheimer's Fraud (4w)
• Whoa Now: Cautionary Tales from Materials Science (1mo)
• Inside a Scientific Paper Mill (1mo)
• Autoimmune Disease, Transformed? (1mo)
• Lose Your Crystalline Form and Go Amorphous (1mo)
• Alzheimer's Update: Infectious Agents and Gamma-Secretase Too (1mo)

• NHS records to be harnessed in pancreatic cancer screening (19h)
• EU kicks off review of GSK's linerixibat in PBC (20h)
• Roche's Hemlibra follow-up set for phase 3 in haemophilia A (20h)
• ADA: Lilly makes its case for oral GLP-1 orforglipron (21h)
• ADA: Novo continues effort to rehabilitate CagriSema (23h)
• Madrigal closes on EU approval of first MASH treatment (3d)
• Grail plans FDA filing for cancer blood test after new trial (3d)
• Dupixent is first FDA-approved drug for rare skin disease (3d)
• FDA blocks trials that send US cells to 'hostile' countries (4d)
• Could a Novo error set up early GLP-1 generics in Canada? (4d)
• Dismay but little surprise as NICE rejects Alzheimer's drugs (5d)
• Gilead's twice-yearly PrEP drug is cleared by FDA (5d)
• Amid sector disruption, biotech must focus on 'fundamentals' (5d)
• Biogen bids to extend use of Skyclarys to younger patients (5d)
• App to support people with depression launches in GB (5d)
• Guidance creates access gap in UK for GPP drug Spevigo (5d)
• Fired ACIP panel says RFK Jr is weakening vaccine programmes (5d)
• UK regulator overhauls medical device regulation (6d)
• Welsh biotech Draig emerges with $140m in financing (6d)
• FDA unveils fast-track review path for 'national priorities' (6d)

• The significance of mAbs in drug discovery and development (31m)
• eBook: The significance of mAbs in drug discovery and development (31m)
• Study supports monovalent antibody in neuropsychiatric disease (20h)
• New discovery could advance drugs for diabetes and obesity (22h)
• New DDW Highlights podcast: 22 June 2025 (1d)
• What international reference pricing could mean for US drug costs (1d)
• DDW Highlights: 22 June 2025 (1d)
• Last chance to register: How is AI innovating in drug discovery? (1d)
• This week in drug discovery (16-20 June) (3d)
• All-in-one vaccine development backed by $12.4m funding (3d)
• Bevacizumab gamma gets Scottish OK for wet AMD (4d)
• Data highlights from EHA 2025 (4d)
• Sphere Bio expands operations in China (4d)
• Study finds heart disease drug promotes bone growth (4d)
• Adding immunotherapy improves survival rates in anal cancer (5d)
• Parallel Bio secures $21m to advance human-first drug discovery (5d)
• Casma takes a new therapeutic approach to neurodegeneration (5d)
• Scientists uncover mechanism behind drug resistance in bowel cancer (5d)
• FDA priority programme reduces drug reviews to two months (6d)
• Expert commentary from ASCO 2025 (6d)

Google News Biotech

• Nurturing biotech company creation - VC Magazin (9m)
• Sonrai and Plectonic Biotech partner to advance cancer immunotherapies - European Biotechnology Magazine (21m)
• Danish Green Biotech Firm Cellugy Secures $9.25 M to Replace Microplastics in Cosmetics - Cosmetics & Toiletries (22m)
• Taiwanese Biotech Delegation Heads to Phoenix, Forging New International Collaborations - geneonline.com (26m)
• 13 Best Biotech Stocks To Invest In Now - Insider Monkey (49m)
• Cell Line Development Market Experiences Rapid Innovation as - openPR.com (1h)
• How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - MSN (1h)
• How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Yahoo Finance (1h)
• How Is Incyte’s Stock Performance Compared To Other Biotech Stocks? - Barchart.com (1h)
• Biotech Startup Utopia Therapeutics Secures $1.5m Investment From Whale Tank To Advance Preclinical Development Of Obesity Vaccine - Passionate In Marketing (1h)
• RTW Biotech Opportunities’ Corxel Pharmaceuticals makes clinical progress - QuotedData (2h)
• Pharmaceutical Biotechnology Environmental Monitoring Market Expected to Grow at 6.5% CAGR from 2025 to 2032 - openPR.com (2h)
• Brawn Biotech Faces Intense Selling Pressure Amid Continued Losses and Underperformance - MarketsMojo (3h)
• Indrayani Biotech Faces Financial Struggles Amidst Sector Outperformance and Declining Investor Confidence - MarketsMojo (3h)
• Indrayani Biotech Faces Operational Challenges Amidst Significant Stock Volatility and Declining Investor Confidence - MarketsMojo (3h)
• Concord Biotech Shows Strong Performance Amid Technical Evaluation Adjustments - MarketsMojo (4h)
• Windlas Biotech Faces Technical Shift Amidst Mixed Market Signals and Growth Concerns - MarketsMojo (4h)
• Biotech breakthrough: UoH alumni launch strategic partnership - The Hans India (4h)
• The Impact of Recent Biotech Lawsuits on Investor Confidence - BNO News (4h)
• Biotech firm Cloudbreak Pharma targets $611 million HK IPO - The Standard (HK) (4h)